Greg Stephenson was born in Anderson, Indiana in 1962. After obtaining a B.S. in Chemistry from Ball State University, he earned a Ph.D. in Medicinal Chemistry from Purdue University for research of the solid-state properties of pharmaceuticals under the advisement of Professor Stephen Byrn. He subsequently joined Eli Lilly and Company in its Material Science and Physical Characterizations group in 1994.
He is currently a Research Advisor to the Preformulation Department, where he is responsible for the company’s small molecule X-ray crystallography laboratory and its Salt Screening groups. He was the recipient of Eli Lilly and Company’s Presidential Award in 1995, 1997, 2004, and 2012. He has authored more than 70 peer-reviewed journal articles, is named as co-inventor on 14 different patents, and has authored three book chapters. He was elected as a Fellow of the International Centre for Diffraction’s awards committee. He serves on the Editorial Advisor Board for The Journal of Pharmaceutical Sciences and Pharmaceutical Development and Technology and also reviews articles for numerous journals. He continues to be fascinated by the crystallization behavior of organic compounds and continues to venture into the laboratory on every possible opportunity.
We maintain the highest standards of scientific and laboratory safety, ensuring that every experiment, analysis, and process is performed with precision and care. The well-being of our team, partners, and the patients ultimately served by our work is our top priority.
We advance pharmaceutical development through continuous scientific discovery. By exploring novel solid forms, crystallization pathways, and analytical approaches, we push the boundaries of what’s possible in solid-state chemistry and preformulation science.
We conduct our research and collaborations with complete transparency, scientific rigor, and ethical responsibility. Our commitment to honest data, reliable results, and unbiased guidance builds enduring trust with every client and partner.
We are dedicated to understanding the unique challenges of each molecule and each client. By delivering tailored solid-form solutions, actionable insights, and responsive scientific support, we help our partners accelerate development and achieve confident outcomes.
Pharmaceutical and Analytical Development Division Material Science and Physical Characterizations Group.
Studied under the advisement of Dr. Stephen R. Byrn, Area of Specialization: Polymorphism and Analytical Chemistry of...
Analytical Chemist responsible for the X-ray Powder Diffraction and Thermal Analytical methods in Analytical Development.
Reviewer for: Crystal Growth and Design, Journal of Pharmaceutical Science, Expert Opinion on Drug and Metabolism & Toxicology, Pharmaceutical Development and Technology, Journal of Pharmaceutical and Biomedical Analysis, Pharmaceutical Research, Chemical Research in Toxicology, Pharmaceutical Development and Technology, and Molecular Pharmaceutics
Fill out the form below, and we’ll schedule a consultation to discuss your solid-state challenges.